March 25, 2021
NeuroPace, maker of an implanted neurostimulation therapy device for uncontrolled epileptic seizures, filed SEC documents yesterday outlining plans to raise as much as $75 million in an IPO listing on the Nasdaq.
The Mountain View, California-based company has been around since 1997 and has brought in a couple hundred million in funding across several rounds, according to CrunchBase. In fact, the...
September 2, 2020
NeuroPace, the maker of an implanted neurostimulation therapy device for uncontrolled epileptic seizures, announced a $33 million equity raise on Monday. Accelmed Partners led the investment, which was joined by new backers such as Revelation Partners, Soleus Capital and an unnamed strategic investor. Prior backers KCK Group and OrbiMed Advisors also contributed.
Alongside the equity, NeuroPace...
October 29, 2018
A new study in the journal Neurology shows that the NightWatch, a connected armband from Leiden, Netherlands-based LivAssured, detected nighttime epileptic seizures 85 percent of the time.
The device has been under development for 20 years by a consortium that includes Kempenhaeghe epilepsy centre, Eindhoven University of Technology, the Foundation for Epilepsy Institutions in the Netherlands (...
February 5, 2018
Empatica's Embrace, the consumer-facing wearable for epileptic seizure detection, received 510(k) clearance from the FDA last month. The wearable, which has already been used in clinical trials by pharma company Sunovion, has a long history that's led it up to this milestone.
The clearance is as a prescription, not an over-the-counter device, which means users will have to secure a prescription...